Evidence map›Paper›PMID 35868022›Full record

ArticleBlood advances2023

Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.

Maximilian Merz, Qiang Hu, Almuth Maria Anni Merz, Jie Wang, Nicholas Hutson, Cherie Rondeau, Kimberly Celotto, Ahmed Belal, Ronald Alberico, AnneMarie W Block and 12 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 2 countries.

Maximilian MerzDepartment of Medicine, Roswell Park Comprehensive Cancer Center (Roswell Park), Buffalo, NY.ORCID 0000-0002-2805-5973
Qiang HuDepartment of Biostatistics and Bioinformatics, Roswell Park, Buffalo, NY.
Almuth Maria Anni MerzDepartment of Medicine, Roswell Park Comprehensive Cancer Center (Roswell Park), Buffalo, NY.
Jie WangDepartment of Biostatistics and Bioinformatics, Roswell Park, Buffalo, NY.
Nicholas HutsonDepartment of Biostatistics and Bioinformatics, Roswell Park, Buffalo, NY.
Cherie RondeauDepartment of Medicine, Roswell Park Comprehensive Cancer Center (Roswell Park), Buffalo, NY.
Kimberly CelottoDepartment of Medicine, Roswell Park Comprehensive Cancer Center (Roswell Park), Buffalo, NY.
Ahmed BelalDepartment of Diagnostic Radiology, Roswell Park, Buffalo, NY.
Ronald AlbericoDepartment of Diagnostic Radiology, Roswell Park, Buffalo, NY.
AnneMarie W BlockClinical Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine, Roswell Park, Buffalo, NY.
Hemn MohammadpourDepartment of Immunology, Roswell Park, Buffalo, NY.ORCID 0000-0002-0158-7283
Paul K WallaceFlow and Image Cytometry, Department of Pathology and Laboratory Medicine, Roswell Park, Buffalo, NY.
Joseph TarioFlow and Image Cytometry, Department of Pathology and Laboratory Medicine, Roswell Park, Buffalo, NY.
Jesse LuceGenomics Shared Resources, Roswell Park, Buffalo, NY.
Sean T GlennGenomics Shared Resources, Roswell Park, Buffalo, NY.
Prashant SinghGenomics Shared Resources, Roswell Park, Buffalo, NY.
Mehmet SamurDepartment of Data Sciences, Dana Farber Cancer Institute, Boston, MA.
Nikhil MunshiDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park, Buffalo, NY.
Philip L McCarthyTransplant and Cellular Therapy Program, Department of Medicine, Roswell Park, Buffalo, NY.ORCID 0000-0002-9577-3879
Lei WeiDepartment of Biostatistics and Bioinformatics, Roswell Park, Buffalo, NY.
Jens HillengassDepartment of Medicine, Roswell Park Comprehensive Cancer Center (Roswell Park), Buffalo, NY.ORCID 0000-0002-1778-0010
Roswell Park Comprehensive Cancer Center · USHarvard University · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C. · 2003 to 2023
$45.0M
Overcoming stress driven suppression of the anti-tumor immune response in cancer - understanding the MDSC piece of the puzzleF32CA239356 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOHAMMADPOUR, HEMN · 2020 to 2021
$80k
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSEI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MUNSHI, NIKHIL C. · 2013 to 2025
–
BLRD VA I01 BX001584NCI NIH HHS F32 CA239356NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA100707
6 · The paper itself

Abstract

Spatial heterogeneity is a common phenomenon in metastatic solid tumors and an evolving concept in multiple myeloma (MM). The interplay between malignant plasma cells (PCs) and the microenvironment has not yet been analyzed in MM. For this purpose, we performed bone marrow aspirates and imaging-guided biopsies of corresponding lesions in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM) patients. PCs were isolated and subjected to whole-exome sequencing (WES). Non-PCs were studied with next-generation flow (NGF) and T-cell receptor sequencing (TCRseq) to analyze the connection between malignant and nonmalignant cells in the bone marrow and in lesions. Although we observed a strong overlap from WES, NGF, and TCRseq in patients with intramedullary disease, WES revealed significant spatial heterogeneity in patients with extramedullary disease. NGF showed significant immunosuppression in RRMM compared with NDMM as indicated by fewer myeloid dendritic cells, unswitched memory B cells, Th9 cells, and CD8 effector memory T cells but more natural killer and regulatory T cells. Additionally, fewer T-cell receptor (TCR) sequences were detected in RRMM compared with NDMM and healthy individuals. After induction therapy, TCR repertoire richness increased to levels of healthy individuals, and NGF showed more regulatory T cells and myeloid-derived suppressor cells, regardless of depth of response. Clinical significance of imaging-guided biopsies of lesions was demonstrated by detection of monoclonal PCs in patients without measurable residual disease (MRD) in aspirates from the iliac crest as well as identification of secondary primary malignancies in MRD- patients. Furthermore, site-specific clones with different drug susceptibilities and genetically defined high-risk features were detected by our workflow.

Indexed as

Multiple MyelomaNeoplasms, Plasma CellBone MarrowHumansPlasma CellsTumor Microenvironment

Identifiers

PMID35868022
PMCPMC9984963
OpenAlexW4286610482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.